THE Veterinary Medicines Directorate (VMD) would like to make veterinarians aware of a recent increase in the number of adverse reaction reports we have received for Augmentin Intravenous Powder for Solution for Injection (amoxicillin and clavulanate) (GlaxoSmithKline).
Over the past three months we have received a significantly higher number of reports relating to Augmentin. They all involved hypersensitivity reactions, including allergic oedema, urticaria and allergic pruritus. We notified veterinary practices of a similar issue in 2011 concerning Co-amoxiclav, which also contains amoxicillin and clavulanate.
Augmentin is authorised for use in humans and is used by veterinary surgeons under the cascade system. It is not authorised for use in animals and, therefore, no safety or efficacy studies have been carried out relating to its use in animals....
© 2001-2024 Fundación Dialnet · Todos los derechos reservados